Article ; Online: Patient's behavior and attitudes toward the management of benign prostatic hyperplasia among patients with the risk of disease progression: prospective study by "Prostate and Expectations of Treatment Epidemiology Research (PETER) study group".
Wiener klinische Wochenschrift
2015 Volume 127, Issue 9-10, Page(s) 363–368
Abstract: Background: The aim of the study was to evaluate patients attitudes with benign prostatic hyperplasia at the risk of progression during a 12-month period of observation.: Materials and methods: A total of 426 patients from 45 outpatients centers were ...
Abstract | Background: The aim of the study was to evaluate patients attitudes with benign prostatic hyperplasia at the risk of progression during a 12-month period of observation. Materials and methods: A total of 426 patients from 45 outpatients centers were included and prospectively followed. Inclusion criteria were: age > 50 years, International Prostate Symptom Score (IPSS) > 8, prostate volume > 30 cm(3) (transabdominal ultrasound) and PSA > 1.5 to < 10 ng/ml. Results: In all, 28.6% patients were naive, 62.9% used monotherapy (alpha-blocker), and 8.5% combined treatment (alpha-blocker/5alpha-reductase inhibitor/dutasteride). The most bothersome symptoms were the weak urine stream (60.8%) and nocturia (59.2%). Patients expectations from the treatment were stabilization of the disease and reducing the risk of surgery rather than rapid resolution of symptoms. Despite the presence of symptoms, 2.3% patients claimed that benign prostatic hyperplasia/lower urinary tract symptoms had no impact on their quality of life (QoL), in 48.1 % only little impact on QoL, and 47.9% patients percepted their symptoms as severe. Out of 71.4% patients treated previously, 26.5% patients were indecisive about the satisfaction of present treatment. Visual analog score was percepted more optimistically rather than the IPSS. Pearson's correlation r = 0.68 at the beginning and r = 0.83 at the end of the study. Conclusions: Prostate and Expectations of Treatment Epidemiology Research study highlights and reflects on patients behavior and self-perception, patients self-perception of the disease and therapeutic priorities during the 1 year of observation. |
---|---|
MeSH term(s) | 5-alpha Reductase Inhibitors/therapeutic use ; Adrenergic alpha-Antagonists/therapeutic use ; Aged ; Aged, 80 and over ; Comorbidity ; Disease Progression ; Drug Therapy, Combination ; Dutasteride/therapeutic use ; Humans ; Lower Urinary Tract Symptoms/epidemiology ; Lower Urinary Tract Symptoms/pathology ; Lower Urinary Tract Symptoms/psychology ; Lower Urinary Tract Symptoms/therapy ; Male ; Middle Aged ; Patient Satisfaction ; Prospective Studies ; Prostate/pathology ; Prostate-Specific Antigen/blood ; Prostatic Hyperplasia/epidemiology ; Prostatic Hyperplasia/pathology ; Prostatic Hyperplasia/psychology ; Prostatic Hyperplasia/therapy ; Research ; Risk ; Ultrasonography |
Chemical Substances | 5-alpha Reductase Inhibitors ; Adrenergic alpha-Antagonists ; Prostate-Specific Antigen (EC 3.4.21.77) ; Dutasteride (O0J6XJN02I) |
Language | English |
Publishing date | 2015-05 |
Publishing country | Austria |
Document type | Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't |
ZDB-ID | 200462-8 |
ISSN | 1613-7671 ; 0043-5325 ; 0300-5178 |
ISSN (online) | 1613-7671 |
ISSN | 0043-5325 ; 0300-5178 |
DOI | 10.1007/s00508-014-0668-4 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 902: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.